Locked nucleic acid (LNA): A modern approach to cancer diagnosis and treatment
Cancer is responsible for about one in six deaths in the world. Conventional cancer treatments like chemotherapy, radiotherapy, and surgery are associated with drug poisoning and poor prognosis. Thanks to advances in RNA delivery and target selection, new cancer medicines are now conceivable to impr...
Saved in:
| Published in | Experimental cell research Vol. 423; no. 1; p. 113442 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.02.2023
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0014-4827 1090-2422 1090-2422 |
| DOI | 10.1016/j.yexcr.2022.113442 |
Cover
| Abstract | Cancer is responsible for about one in six deaths in the world. Conventional cancer treatments like chemotherapy, radiotherapy, and surgery are associated with drug poisoning and poor prognosis. Thanks to advances in RNA delivery and target selection, new cancer medicines are now conceivable to improve the quality of life and extend the lives of cancer patients. Antisense oligonucleotides (ASOs) and siRNAs are the most important tools in RNA therapies. Locked Nucleic Acids (LNAs) are one of the newest RNA analogs, exhibiting more affinity to binding, sequence specificity, thermal stability, and nuclease resistance due to their unique properties. Assays using LNA are also used in molecular diagnostic methods and provide accurate and rapid mutation detection that improves specificity and sensitivity. This study aims to review the special properties of LNA oligonucleotides that make them safe and effective antisense drugs for cancer treatment by controlling gene expression. Following that, we go over all of the molecular detection methods and cancer treatment antisense tactics that are possible with LNA technology. |
|---|---|
| AbstractList | Cancer is responsible for about one in six deaths in the world. Conventional cancer treatments like chemotherapy, radiotherapy, and surgery are associated with drug poisoning and poor prognosis. Thanks to advances in RNA delivery and target selection, new cancer medicines are now conceivable to improve the quality of life and extend the lives of cancer patients. Antisense oligonucleotides (ASOs) and siRNAs are the most important tools in RNA therapies. Locked Nucleic Acids (LNAs) are one of the newest RNA analogs, exhibiting more affinity to binding, sequence specificity, thermal stability, and nuclease resistance due to their unique properties. Assays using LNA are also used in molecular diagnostic methods and provide accurate and rapid mutation detection that improves specificity and sensitivity. This study aims to review the special properties of LNA oligonucleotides that make them safe and effective antisense drugs for cancer treatment by controlling gene expression. Following that, we go over all of the molecular detection methods and cancer treatment antisense tactics that are possible with LNA technology. Cancer is responsible for about one in six deaths in the world. Conventional cancer treatments like chemotherapy, radiotherapy, and surgery are associated with drug poisoning and poor prognosis. Thanks to advances in RNA delivery and target selection, new cancer medicines are now conceivable to improve the quality of life and extend the lives of cancer patients. Antisense oligonucleotides (ASOs) and siRNAs are the most important tools in RNA therapies. Locked Nucleic Acids (LNAs) are one of the newest RNA analogs, exhibiting more affinity to binding, sequence specificity, thermal stability, and nuclease resistance due to their unique properties. Assays using LNA are also used in molecular diagnostic methods and provide accurate and rapid mutation detection that improves specificity and sensitivity. This study aims to review the special properties of LNA oligonucleotides that make them safe and effective antisense drugs for cancer treatment by controlling gene expression. Following that, we go over all of the molecular detection methods and cancer treatment antisense tactics that are possible with LNA technology.Cancer is responsible for about one in six deaths in the world. Conventional cancer treatments like chemotherapy, radiotherapy, and surgery are associated with drug poisoning and poor prognosis. Thanks to advances in RNA delivery and target selection, new cancer medicines are now conceivable to improve the quality of life and extend the lives of cancer patients. Antisense oligonucleotides (ASOs) and siRNAs are the most important tools in RNA therapies. Locked Nucleic Acids (LNAs) are one of the newest RNA analogs, exhibiting more affinity to binding, sequence specificity, thermal stability, and nuclease resistance due to their unique properties. Assays using LNA are also used in molecular diagnostic methods and provide accurate and rapid mutation detection that improves specificity and sensitivity. This study aims to review the special properties of LNA oligonucleotides that make them safe and effective antisense drugs for cancer treatment by controlling gene expression. Following that, we go over all of the molecular detection methods and cancer treatment antisense tactics that are possible with LNA technology. |
| ArticleNumber | 113442 |
| Author | Fatemi, Somayeh Ahmadifard, Mohamadreza Salehi, Mohammad Khoshghiafeh, Azin Kamali, Mohammad Javad Moradi, Fereshteh |
| Author_xml | – sequence: 1 givenname: Mohammad Javad surname: Kamali fullname: Kamali, Mohammad Javad organization: Department of Medical Genetics, School of Medicine, Babol University of Medical Sciences, Babol, Iran – sequence: 2 givenname: Mohammad surname: Salehi fullname: Salehi, Mohammad organization: School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran – sequence: 3 givenname: Somayeh surname: Fatemi fullname: Fatemi, Somayeh organization: Department of Medical Genetics, School of Medicine, Babol University of Medical Sciences, Babol, Iran – sequence: 4 givenname: Fereshteh surname: Moradi fullname: Moradi, Fereshteh organization: Department of Medical Genetics, School of Medicine, Babol University of Medical Sciences, Babol, Iran – sequence: 5 givenname: Azin surname: Khoshghiafeh fullname: Khoshghiafeh, Azin organization: Department of Medical Genetics, School of Medicine, Babol University of Medical Sciences, Babol, Iran – sequence: 6 givenname: Mohamadreza surname: Ahmadifard fullname: Ahmadifard, Mohamadreza email: mr.ahmadifard@gmail.com organization: Department of Medical Genetics, School of Medicine, Babol University of Medical Sciences, Babol, Iran |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36521777$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kDtvFDEURi2UiGwCvwAJuQzFbHxtzwuJYhXxklZJE2rLc30HvMzYi-1F5N8zYZOGItVtzvl0dc7ZSYiBGHsDYg0Cmqvd-p7-YFpLIeUaQGktX7AViF5UUkt5wlZCgK50J9szdp7zTgjRddC8ZGeqqSW0bbtiN9uIP8nxcMCJPHKL3vHL7c3m3Xu-4XN0lAK3-32KFn_wEjnagJS48_Z7iNlnboPjJZEtM4Xyip2Odsr0-vFesG-fPt5df6m2t5-_Xm-2Faq6L5XqqXNajrrudV-LcYCml4JANa0S4wiDcK0UnUQYZa_JDYMC2zRAOIw0OFQX7PK4uzz260C5mNlnpGmygeIhG9nWdd3WWsGCvn1ED8NMzuyTn226N08NFqA_AphizolGg77Y4mMoyfrJgDAPvc3O_OttHnqbY-_FVf-5T_PPWx-OFi2JfntKJqOnpavzibAYF_2z_l_osZi2 |
| CitedBy_id | crossref_primary_10_1002_adhm_202401207 crossref_primary_10_1016_j_snb_2023_134375 crossref_primary_10_1016_j_trac_2024_118063 crossref_primary_10_1016_j_jct_2024_107399 crossref_primary_10_2174_0113816128303695240512141729 crossref_primary_10_1016_j_bios_2024_116406 crossref_primary_10_1007_s10528_025_11078_3 crossref_primary_10_1016_j_microc_2025_112737 crossref_primary_10_3390_antiox13060678 crossref_primary_10_1002_chem_202401580 crossref_primary_10_1016_j_jdiacomp_2023_108524 crossref_primary_10_1080_17576180_2024_2368340 crossref_primary_10_3389_fcell_2024_1390704 crossref_primary_10_1002_ardp_202400404 crossref_primary_10_3390_ijms242417523 crossref_primary_10_1007_s12094_024_03822_9 crossref_primary_10_1007_s12033_023_00767_2 crossref_primary_10_1038_s41392_024_02035_4 crossref_primary_10_1038_s41392_024_02039_0 crossref_primary_10_3389_fimmu_2024_1441733 crossref_primary_10_1016_j_canlet_2024_217297 crossref_primary_10_1016_j_rechem_2024_101648 crossref_primary_10_3389_fonc_2025_1534862 crossref_primary_10_1021_acs_jmedchem_3c00551 crossref_primary_10_1002_adtp_202400231 crossref_primary_10_1016_j_exger_2023_112287 |
| Cites_doi | 10.1007/978-1-0716-1581-2_8 10.1093/nar/gkp841 10.1016/S1359-6349(04)80224-6 10.1007/s00262-019-02438-1 10.1111/j.1742-4658.2009.06908.x 10.1371/journal.pone.0211651 10.1016/j.addr.2015.05.008 10.5306/wjco.v10.i3.149 10.1039/C5CC02756J 10.1128/MCB.02005-06 10.1038/nbt.2376 10.1016/S0040-4020(98)00094-5 10.1016/bs.acc.2017.10.002 10.1089/154545704322988067 10.1093/nar/gkl1071 10.1093/nar/19.20.5551 10.1089/108729002760070849 10.1007/978-94-007-4549-0_39 10.1074/jbc.M311683200 10.1126/science.1178178 10.1038/bjc.2013.619 10.1038/sj.bjc.6603466 10.1073/pnas.88.18.8237 10.1093/nar/gki193 10.1023/A:1011958726518 10.1016/j.jim.2014.03.004 10.1093/nar/gkf651 10.1186/bcr2803 10.1101/gr.1858004 10.1093/nar/gkt127 10.1016/j.ymthe.2006.05.017 10.1007/s12015-019-09944-w 10.1517/14728222.2016.1164693 10.1093/nar/gkv964 10.1016/j.semcancer.2008.01.004 10.1182/blood-2018-03-836601 10.1021/bi0485732 10.1177/1010428317692261 10.1093/nar/gkg820 10.1186/s12885-016-2867-z 10.1158/1078-0432.CCR-10-2277 10.1371/journal.pone.0085350 10.1021/bi025907j 10.18632/oncotarget.820 10.1016/j.ddtec.2005.08.012 10.1201/9780849387951.ch19 10.1186/s12935-020-01394-6 10.1016/j.cca.2016.04.005 10.1081/NCN-100002312 10.1158/1538-7445.NONRNA15-A20 10.1080/15257770701542132 10.1042/BST0371022 10.1186/s13046-018-0767-6 10.1158/1538-7445.AM2013-3486 10.1109/MEMB.2005.1463401 10.1016/j.drudis.2017.09.018 10.1038/srep37721 10.21873/anticanres.11623 10.1016/j.molcel.2007.05.017 10.1073/pnas.97.10.5633 10.1182/blood-2012-02-410647 10.1016/S0016-5085(08)63492-7 10.18632/oncotarget.12043 10.1016/S0040-4039(97)10322-7 10.1016/S0040-4039(98)00706-0 10.1021/bc034145h 10.2174/138161208784246234 10.1093/nar/30.9.1911 10.1002/humu.10228 10.1038/cgt.2016.10 10.1038/ng.786 10.4238/2015.May.22.14 10.1158/0008-5472.CAN-05-0331 10.1038/s41598-017-09147-8 10.1016/S1359-6349(10)71758-4 10.1021/jo9806658 10.1158/1078-0432.CCR-15-0489 10.1186/s12867-018-0107-6 10.1021/acsnano.8b01198 10.2165/00063030-200721040-00004 10.1021/ja0168763 10.1016/j.ijpharm.2013.05.049 10.1016/S1074-5521(00)00058-2 10.1093/nar/gkx056 10.1007/978-1-4939-1221-6_9 10.1038/sj.onc.1210425 10.4161/rna.6.3.8807 10.1080/15476286.2018.1445959 10.1016/S1046-2023(05)80124-0 10.1021/jp506703g 10.1021/acschembio.7b00749 10.1038/gt.2010.133 10.1021/acs.analchem.6b02608 10.1006/jmbi.1993.1528 10.1371/journal.pone.0089659 10.1016/j.jpba.2020.113451 10.1039/a708608c 10.1158/1078-0432.CCR-08-3257 10.1038/nmeth1067 10.1016/j.ijpharm.2019.118729 10.1021/jp4016068 10.15252/emmm.201100899 10.1016/S0167-7799(02)00038-0 10.1158/1078-0432.CCR-20-3139 10.1089/nat.2015.0550 10.1074/jbc.M701805200 10.1093/nar/gnh036 10.3390/cancers12010027 10.1007/s00216-014-7618-x 10.1089/1545457041526317 10.1016/S1359-6349(03)90737-3 10.3410/B3-9 10.1007/3-540-27262-3_21 10.1016/j.talanta.2016.04.008 10.1039/a801571f 10.1093/nar/30.11.2435 10.1126/science.1114519 |
| ContentType | Journal Article |
| Copyright | 2022 Elsevier Inc. Copyright © 2022 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2022 Elsevier Inc. – notice: Copyright © 2022 Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.yexcr.2022.113442 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1090-2422 |
| ExternalDocumentID | 36521777 10_1016_j_yexcr_2022_113442 S0014482722004359 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M -DZ -~X .~1 0R~ 1B1 1RT 1~. 1~5 4.4 457 4G. 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAXUO ABFNM ABFRF ABGSF ABJNI ABMAC ABOCM ABPPZ ABUDA ABYKQ ACDAQ ACGFO ACGFS ACNCT ACPRK ACRLP ADBBV ADEZE ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJOXV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLXMC C45 CS3 DM4 DOVZS DU5 EBS EFBJH EFLBG EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IHE J1W K-O KOM L7B LG5 LX2 M41 MO0 N9A O-L O9- OAUVE OVD OZT P-8 P-9 P2P PC. PQQKQ Q38 RNS ROL RPZ SCC SDF SDG SDP SES SPCBC SSU SSZ T5K TEORI TWZ VQA WH7 Y6R YZZ ZA5 ZCA ZMT ZU3 ~G- ~KM .55 .GJ 29G 3O- 53G 9M8 AAQXK AATTM AAXKI AAYWO AAYXX ABDPE ABEFU ABWVN ABXDB ACKIV ACRPL ACVFH ADCNI ADFGL ADMUD ADNMO ADVLN ADXHL AEIPS AETEA AEUPX AFJKZ AFPUW AGCQF AGHFR AGQPQ AGRDE AGRNS AI. AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP ASPBG AVWKF AZFZN BNPGV CAG CITATION COF EJD FA8 FEDTE FGOYB G-2 HLW HVGLF HZ~ LPU MVM NEJ OHT R2- RIG SBG SEW SSH VH1 WUQ X7L X7M XOL XPP YYP ZGI ZKB CGR CUY CVF ECM EIF NPM 7X8 EFKBS |
| ID | FETCH-LOGICAL-c359t-39e8d42f4594950fb16920e136730ff1b0d72082c1f294edbb31a661ecbfebdc3 |
| IEDL.DBID | AIKHN |
| ISSN | 0014-4827 1090-2422 |
| IngestDate | Fri Sep 05 07:34:23 EDT 2025 Thu Apr 03 07:02:39 EDT 2025 Thu Apr 24 22:53:31 EDT 2025 Tue Jul 01 02:49:01 EDT 2025 Fri Feb 23 02:39:32 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Locked nucleic acid Cancer diagnosis Cancer treatment LNA Cancer |
| Language | English |
| License | Copyright © 2022 Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c359t-39e8d42f4594950fb16920e136730ff1b0d72082c1f294edbb31a661ecbfebdc3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 36521777 |
| PQID | 2755575431 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2755575431 pubmed_primary_36521777 crossref_citationtrail_10_1016_j_yexcr_2022_113442 crossref_primary_10_1016_j_yexcr_2022_113442 elsevier_sciencedirect_doi_10_1016_j_yexcr_2022_113442 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-02-01 2023-02-00 20230201 |
| PublicationDateYYYYMMDD | 2023-02-01 |
| PublicationDate_xml | – month: 02 year: 2023 text: 2023-02-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Experimental cell research |
| PublicationTitleAlternate | Exp Cell Res |
| PublicationYear | 2023 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Li, Matsui, Corey (bib34) 2016; 7 Eva Van Rooij, Montgomery, inventor (bib31) 2013 Di Martino, Gullà, Gallo Cantafio, Altomare, Amodio, Leone (bib79) 2014; 9 Di Martino, Gullà, Cantafio, Lionetti, Leone, Amodio (bib84) 2013; 4 Yildirim, Kierzek, Kierzek, Schatz (bib22) 2014; 118 Veedu, Wengel (bib26) 2009; 6 Skronski, Chorostowska-Wynimko, Szczepulska, Szpechcinski, Rudzinski, Orlowski (bib111) 2013; 756 Manoharan (bib48) 2002; 12 Orum (bib57) 2005; 24 Torres, Kozak, Korolczuk, Wdowiak, Domańska-Glonek, Maciejewski (bib87) 2016; 16 Fazil, Ong, Chalasani, Low, Kizhakeyil, Mamidi (bib51) 2016; 6 Stenvang, Silahtaroglu, Lindow, Elmen, Kauppinen (bib67) 2008; 18 Gui, Wang, Li, Zhu, Yu, Xun (bib118) 2016; 154 Koshkin, Rajwanshi, Wengel (bib11) 1998; 39 Sokilde, Glue, Stahlberg, Rasmussen, Jacobsen, Nielsen (bib125) 2007; 67 Lanford, Hildebrandt-Eriksen, Petri, Persson, Lindow, Munk (bib36) 2010; 327 Dean, Elias, Jamilpour, Utzinger, Wong (bib117) 2016; 88 Rigo, Seth, Bennett (bib32) 2014; 825 Wu, Lima, Zhang, Fan, Sun, Crooke (bib37) 2004; 279 Elmen, Thonberg, Ljungberg, Frieden, Westergaard, Xu (bib58) 2005; 33 Eggert, Schmitz, Koenig, Asadullah, Krahn, Stresemann (bib120) 2013; 73 Mouritzen, Lomholt, Echwald, Noerholm (bib28) 2012 Cerritelli, Crouch (bib40) 2009; 276 Morinaga, Nakamura, Atsumi, Murakawa, Yamaoku, Aoyama (bib73) 2016; 36 Kauppinen, Vester, Wengel (bib97) 2006; 173 Akhtar, Basu, Wickstrom, Juliano (bib46) 1991; 19 Sorensen, Jorgensen, Nederby, Hokland, Nyvold (bib112) 2014; 406 Edwards, Poongavanam, Kanwar, Roy, Hillman, Prasad (bib106) 2015; 51 Mads Detlef Sorensen JW, Troels Koch, Signe M. Christensen, Christoph Rosenbohm, Daniel Sejer Pedersen, Inventor; roche innovation center copenhagen AS, assignee. Synth. Locked Nucleic Acid Deriv.. Canada 2003. Hoeg, Thrue, Oerum, Kristjansen (bib56) 2003; 1 Tian, Chen, Luan, Singh, Yang, Gates (bib116) 2018; 12 Kole, Vacek, Williams (bib59) 2004; 14 Singh S, Koshkin A, Wengel, Nielsen (bib3) 1998 Yamamichi, Shimomura, Inada, Sakurai, Haraguchi, Ozaki (bib74) 2009; 15 Ugozzoli, Wallace (bib114) 1991; 2 Koshkin, Singh, Nielsen, Rajwanshi, Kumar, Meldgaard (bib5) 1998; 54 Nielsen, Larsen, Hoffding, Nhat, Madsen, Moller (bib132) 2021; 2348 Nagai, Miyazawa, Huqun, Tanaka, Udagawa, Kato (bib108) 2005; 65 Kurreck, Wyszko, Gillen, Erdmann (bib20) 2002; 30 Santolla, Lappano, Cirillo, Rigiracciolo, Sebastiani, Abonante (bib86) 2018; 37 Gullà, Di Martino, Gallo Cantafio, Morelli, Amodio, Botta (bib127) 2016; 22 Lindow, Vornlocher, Riley, Kornbrust, Burchard, Whiteley (bib42) 2012; 30 Litman, Jacobsen, Nørholm, Glue, Stahlberg, Møller (bib124) 2007; 4 Obad, dos Santos, Petri, Heidenblad, Broom, Ruse (bib63) 2011; 43 Sutani, Nagai, Udagawa, Uchida, Koyama, Murayama (bib109) 2006; 95 Subramanian, Kanwar, Kanwar, Krishnakumar (bib105) 2015; 25 (bib104) 2005 Hagedorn, Hansen, Koch, Lindow (bib41) 2017; 45 Breitenbuecher, Hoffarth, Worm, Cortes-Incio, Gauler, Köhler (bib123) 2014; 9 van Rooij, Kauppinen (bib35) 2014; 6 Castanotto, Lin, Kowolik, Wang, Ren, Soifer (bib39) 2015; 43 Swayze, Siwkowski, Wancewicz, Migawa, Wyrzykiewicz, Hung (bib100) 2007; 35 Gallo Cantafio, Nielsen, Mignogna, Arbitrio, Botta, Frandsen (bib80) 2016; 5 Bianchini, Omlin, Pezaro, Lorente, Ferraldeschi, Mukherji (bib102) 2013; 109 Lima, Carvalho, Pinto-Ribeiro, Almeida, Wengel, Cerqueira (bib82) 2018; 19 Mettlen, Pucadyil, Ramachandran, Schmid (bib50) 2009; 37 Bandaru R, Zhao J, Richards M, Wu D, Xia J, Zhao H, et al. Novel Releasable PEG-Conjugates of LNA Antisense Oligonucleotides as Potent mRNA Antagonists to Cancer Targets. Raver-Shapira, Marciano, Meiri, Spector, Rosenfeld, Moskovits (bib130) 2007; 26 Braasch, Corey (bib8) 2001; 8 Jepsen, Sorensen, Wengel (bib18) 2004; 14 Wahlestedt, Salmi, Good, Kela, Johnsson, Hökfelt (bib43) 2000; 97 Chen, Huang, Xia, Duan, Chuai, Yang (bib113) 2014; 406 Braasch, Liu, Corey (bib55) 2002; 30 Wu, Contratto, Shanbhogue, Manji, O'Neil, Noonan (bib98) 2019; 10 Zhang, Qu, Kim, Shi, Liao, Kraft (bib90) 2011; 18 Esteller (bib2) 2011; 3 Di Martino, Arbitrio, Fonsi, Erratico, Scionti, Caracciolo (bib81) 2019; 12 Troels Koch, Pedersen (bib30) 2001 Wienholds, Kloosterman, Miska, Alvarez-Saavedra, Berezikov, De Bruijn (bib126) 2005; 309 Anastasiadou, Seto, Beatty, Hermreck, Gilles, Stroopinsky (bib71) 2021; 27 Mirihana Arachchilage, Kharel, Reid, Basu (bib70) 2018; 13 Yan, Wu, Zhang, Li, Liao, Hou (bib64) 2011; 13 Wengel, Koshkin, Singh, Nielsen, Meldgaard, Rajwanshi (bib4) 2006; 18 Deng, Qin, Luo, Liang, Zou (bib99) 2015; 14 Bianchini, Omlin, Pezaro, Lorente, Ferraldeschi, Mukherji (bib92) 2013; 109 Zhang, Roccaro, Rombaoa, Flores, Obad, Fernandes (bib65) 2012; 120 Hol, Leerdam van, Boersma, Kuipers, Wiemer (bib121) 2008; 134 Alam, Ming, Dixit, Fisher, Chen, Juliano (bib47) 2010 Javanmard, Vaseghi, Ghasemi, Rafiee, Ferns, Esfahani (bib72) 2020; 20 Vandghanooni, Eskandani, Barar, Omidi (bib68) 2020; 573 Hansen, Westergaard, Thrue, Asklund, Oerum, Frieden (bib94) 2004; 8 Petersen, Wengel (bib9) 2003; 21 Ishige, Itoga, Matsushita, Nomura (bib122) 2016; 457 Curwen, Eyras, Andrews, Clarke, Mongin, Searle (bib1) 2004; 14 Obika, Nanbu, Hari, Morio, In, Ishida (bib12) 1997; 38 Koch, Ørum (bib16) 2007 Di Giusto, King (bib17) 2004; 32 Hagedorn, Persson, Funder, Albaek, Diemer, Hansen (bib25) 2018; 23 Vester, Wengel (bib10) 2004; 43 Torres, Kozak, Korolczuk, Rycak, Wdowiak, Maciejewski (bib77) 2016; 7 Sørensen, Kværnø, Bryld, Håkansson, Verbeure, Gaubert (bib44) 2002; 124 Pabon-Martinez, Xu, Villa, Lundin, Geny, Nguyen (bib23) 2017; 7 Xu, Gissberg, Pabon-Martinez, Wengel, Lundin, Smith (bib24) 2019; 14 Kole, Krieg (bib33) 2015; 87 Dono, Massucco, Chiara, Sonaglio, Mora, Truini (bib107) 2013; 18 Grünweller, Hartmann (bib61) 2016; 71 Juliano, Alahari, Yoo, Kole, Cho (bib53) 1999; 16 Lima, Cerqueira, Figueiredo, Oliveira, Azevedo (bib62) 2018; 15 Stein, Hansen, Lai, Wu, Voskresenskiy, H (bib49) 2010; 38 Elayadi, Braasch, Corey (bib95) 2002; 41 Morelli, Biamonte, Federico, Amodio, Di Martino, Gallo Cantafio (bib85) 2018; 132 Linsley, Schelter, Burchard, Kibukawa, Martin, Bartz (bib129) 2007; 27 Frieden, Orum (bib54) 2008; 14 Matsubara, Takeuchi, Nishikawa, Yanagisawa, Hayashita, Ebi (bib131) 2007; 26 Fisker, Westergaard, Hansen, Hansen (bib91) 2007; 26 Arcila, Oxnard, Nafa, Riely, Solomon, Zakowski (bib119) 2011; 17 Nedaeinia, Sharifi, Avan, Kazemi, Nabinejad, Ferns (bib75) 2017; 39 Klar, Michel, Schell, Hinterwimmer, Zippelius, Jaschinski (bib101) 2020; 69 Griveau, Bejaud, Anthiya, Avril, Autret, Garcion (bib76) 2013; 454 Ishige, Itoga, Matsushita (bib14) 2018; 83 Franzoni, Morbioli, Turtoro, Solazzo, Greco, Arbitrio (bib78) 2020; 188 Roberts, Palma, Sazani, Orum, Cho, Kole (bib60) 2006; 14 Nielsen, Rasmussen, Kumar, Wengel, Jacobsen, Petersen (bib6) 2004; 15 Pontius, Berg (bib52) 1991; 88 Yoshida, Kim, Ozasa, Nagai, Sakamori, Tsuji (bib110) 2017; 37 Naseri, Oskuee, Forouzandeh-Moghadam, Jaafari (bib69) 2020; 16 Di Martino, Rossi, Caracciolo, Gullà, Tagliaferri, Tassone (bib83) 2016; 20 Grünweller, Hartmann (bib27) 2007; 21 Egawa, Jingushi, Ueda, Kitae, Nakata, Fujita (bib89) 2016; 76 Suresh, Priyakumar (bib21) 2013; 117 Dumble ML, Zhang Y, Zhu P, Kim S, Qu Z, Shi V, et al., editors. 53 Down Regulation of Beta-Catenin by a Locked Nucleic Acid Oligonucleotide Antagonist Inhibits Tumor Growth in Experimental Models of Human Cancer2010. Frieden, Christensen, Mikkelsen, Rosenbohm, Thrue, Westergaard (bib19) 2003; 31 Ahmadi, Sharifi, Salehi (bib88) 2016; 23 Wengel, Petersen, Nielsen, Jensen, Hakansson, Kumar (bib15) 2001; 20 Singh, Wengel (bib13) 1998 Singh, Kumar, Wengel (bib7) 1998; 63 Cogoi, Zorzet, Rapozzi, Géci, Pedersen, Xodo (bib66) 2013; 41 Galardi, Mercatelli, Giorda, Massalini, Frajese, Ciafrè (bib128) 2007; 282 Crinelli, Bianchi, Gentilini, Magnani (bib45) 2002; 30 Fedoroff, Salazar, Reid (bib38) 1993; 233 Latorra, Campbell, Wolter, Hurley (bib115) 2003; 22 Kauppinen, Vester, Wengel (bib96) 2005; 2 Morelli (10.1016/j.yexcr.2022.113442_bib85) 2018; 132 Pontius (10.1016/j.yexcr.2022.113442_bib52) 1991; 88 Tian (10.1016/j.yexcr.2022.113442_bib116) 2018; 12 Crinelli (10.1016/j.yexcr.2022.113442_bib45) 2002; 30 Kauppinen (10.1016/j.yexcr.2022.113442_bib97) 2006; 173 Cerritelli (10.1016/j.yexcr.2022.113442_bib40) 2009; 276 Hagedorn (10.1016/j.yexcr.2022.113442_bib41) 2017; 45 Bianchini (10.1016/j.yexcr.2022.113442_bib92) 2013; 109 Grünweller (10.1016/j.yexcr.2022.113442_bib61) 2016; 71 Morinaga (10.1016/j.yexcr.2022.113442_bib73) 2016; 36 Fedoroff (10.1016/j.yexcr.2022.113442_bib38) 1993; 233 Wengel (10.1016/j.yexcr.2022.113442_bib15) 2001; 20 Esteller (10.1016/j.yexcr.2022.113442_bib2) 2011; 3 Koshkin (10.1016/j.yexcr.2022.113442_bib5) 1998; 54 Alam (10.1016/j.yexcr.2022.113442_bib47) 2010 Nagai (10.1016/j.yexcr.2022.113442_bib108) 2005; 65 Wengel (10.1016/j.yexcr.2022.113442_bib4) 2006; 18 Castanotto (10.1016/j.yexcr.2022.113442_bib39) 2015; 43 Subramanian (10.1016/j.yexcr.2022.113442_bib105) 2015; 25 Nedaeinia (10.1016/j.yexcr.2022.113442_bib75) 2017; 39 Galardi (10.1016/j.yexcr.2022.113442_bib128) 2007; 282 Koshkin (10.1016/j.yexcr.2022.113442_bib11) 1998; 39 Koch (10.1016/j.yexcr.2022.113442_bib16) 2007 Li (10.1016/j.yexcr.2022.113442_bib34) 2016; 7 Santolla (10.1016/j.yexcr.2022.113442_bib86) 2018; 37 Mouritzen (10.1016/j.yexcr.2022.113442_bib28) 2012 Frieden (10.1016/j.yexcr.2022.113442_bib54) 2008; 14 Swayze (10.1016/j.yexcr.2022.113442_bib100) 2007; 35 (10.1016/j.yexcr.2022.113442_bib104) 2005 Mettlen (10.1016/j.yexcr.2022.113442_bib50) 2009; 37 Singh (10.1016/j.yexcr.2022.113442_bib13) 1998 Mirihana Arachchilage (10.1016/j.yexcr.2022.113442_bib70) 2018; 13 Edwards (10.1016/j.yexcr.2022.113442_bib106) 2015; 51 Juliano (10.1016/j.yexcr.2022.113442_bib53) 1999; 16 Di Martino (10.1016/j.yexcr.2022.113442_bib81) 2019; 12 Rigo (10.1016/j.yexcr.2022.113442_bib32) 2014; 825 Wu (10.1016/j.yexcr.2022.113442_bib37) 2004; 279 Anastasiadou (10.1016/j.yexcr.2022.113442_bib71) 2021; 27 Arcila (10.1016/j.yexcr.2022.113442_bib119) 2011; 17 Hagedorn (10.1016/j.yexcr.2022.113442_bib25) 2018; 23 Wahlestedt (10.1016/j.yexcr.2022.113442_bib43) 2000; 97 Eva Van Rooij (10.1016/j.yexcr.2022.113442_bib31) 2013 Suresh (10.1016/j.yexcr.2022.113442_bib21) 2013; 117 10.1016/j.yexcr.2022.113442_bib93 Di Martino (10.1016/j.yexcr.2022.113442_bib83) 2016; 20 Zhang (10.1016/j.yexcr.2022.113442_bib65) 2012; 120 Kurreck (10.1016/j.yexcr.2022.113442_bib20) 2002; 30 Lindow (10.1016/j.yexcr.2022.113442_bib42) 2012; 30 Hoeg (10.1016/j.yexcr.2022.113442_bib56) 2003; 1 Yoshida (10.1016/j.yexcr.2022.113442_bib110) 2017; 37 Latorra (10.1016/j.yexcr.2022.113442_bib115) 2003; 22 Singh S (10.1016/j.yexcr.2022.113442_bib3) 1998 Raver-Shapira (10.1016/j.yexcr.2022.113442_bib130) 2007; 26 Elayadi (10.1016/j.yexcr.2022.113442_bib95) 2002; 41 Vandghanooni (10.1016/j.yexcr.2022.113442_bib68) 2020; 573 Obika (10.1016/j.yexcr.2022.113442_bib12) 1997; 38 Roberts (10.1016/j.yexcr.2022.113442_bib60) 2006; 14 Petersen (10.1016/j.yexcr.2022.113442_bib9) 2003; 21 Litman (10.1016/j.yexcr.2022.113442_bib124) 2007; 4 Vester (10.1016/j.yexcr.2022.113442_bib10) 2004; 43 Griveau (10.1016/j.yexcr.2022.113442_bib76) 2013; 454 Franzoni (10.1016/j.yexcr.2022.113442_bib78) 2020; 188 Fazil (10.1016/j.yexcr.2022.113442_bib51) 2016; 6 Yan (10.1016/j.yexcr.2022.113442_bib64) 2011; 13 Lanford (10.1016/j.yexcr.2022.113442_bib36) 2010; 327 Braasch (10.1016/j.yexcr.2022.113442_bib55) 2002; 30 Sokilde (10.1016/j.yexcr.2022.113442_bib125) 2007; 67 Egawa (10.1016/j.yexcr.2022.113442_bib89) 2016; 76 Fisker (10.1016/j.yexcr.2022.113442_bib91) 2007; 26 Lima (10.1016/j.yexcr.2022.113442_bib62) 2018; 15 Hansen (10.1016/j.yexcr.2022.113442_bib94) 2004; 8 10.1016/j.yexcr.2022.113442_bib29 Gallo Cantafio (10.1016/j.yexcr.2022.113442_bib80) 2016; 5 Nielsen (10.1016/j.yexcr.2022.113442_bib132) 2021; 2348 Nielsen (10.1016/j.yexcr.2022.113442_bib6) 2004; 15 Di Martino (10.1016/j.yexcr.2022.113442_bib79) 2014; 9 Kole (10.1016/j.yexcr.2022.113442_bib59) 2004; 14 Stenvang (10.1016/j.yexcr.2022.113442_bib67) 2008; 18 Ishige (10.1016/j.yexcr.2022.113442_bib122) 2016; 457 Akhtar (10.1016/j.yexcr.2022.113442_bib46) 1991; 19 Zhang (10.1016/j.yexcr.2022.113442_bib90) 2011; 18 Curwen (10.1016/j.yexcr.2022.113442_bib1) 2004; 14 Lima (10.1016/j.yexcr.2022.113442_bib82) 2018; 19 Manoharan (10.1016/j.yexcr.2022.113442_bib48) 2002; 12 Deng (10.1016/j.yexcr.2022.113442_bib99) 2015; 14 Dean (10.1016/j.yexcr.2022.113442_bib117) 2016; 88 Linsley (10.1016/j.yexcr.2022.113442_bib129) 2007; 27 Frieden (10.1016/j.yexcr.2022.113442_bib19) 2003; 31 Bianchini (10.1016/j.yexcr.2022.113442_bib102) 2013; 109 Javanmard (10.1016/j.yexcr.2022.113442_bib72) 2020; 20 Braasch (10.1016/j.yexcr.2022.113442_bib8) 2001; 8 Torres (10.1016/j.yexcr.2022.113442_bib77) 2016; 7 Orum (10.1016/j.yexcr.2022.113442_bib57) 2005; 24 Grünweller (10.1016/j.yexcr.2022.113442_bib27) 2007; 21 Hol (10.1016/j.yexcr.2022.113442_bib121) 2008; 134 Klar (10.1016/j.yexcr.2022.113442_bib101) 2020; 69 Ishige (10.1016/j.yexcr.2022.113442_bib14) 2018; 83 Xu (10.1016/j.yexcr.2022.113442_bib24) 2019; 14 Yamamichi (10.1016/j.yexcr.2022.113442_bib74) 2009; 15 Naseri (10.1016/j.yexcr.2022.113442_bib69) 2020; 16 Di Martino (10.1016/j.yexcr.2022.113442_bib84) 2013; 4 10.1016/j.yexcr.2022.113442_bib103 Wienholds (10.1016/j.yexcr.2022.113442_bib126) 2005; 309 Eggert (10.1016/j.yexcr.2022.113442_bib120) 2013; 73 van Rooij (10.1016/j.yexcr.2022.113442_bib35) 2014; 6 Dono (10.1016/j.yexcr.2022.113442_bib107) 2013; 18 Kole (10.1016/j.yexcr.2022.113442_bib33) 2015; 87 Pabon-Martinez (10.1016/j.yexcr.2022.113442_bib23) 2017; 7 Cogoi (10.1016/j.yexcr.2022.113442_bib66) 2013; 41 Sorensen (10.1016/j.yexcr.2022.113442_bib112) 2014; 406 Gui (10.1016/j.yexcr.2022.113442_bib118) 2016; 154 Skronski (10.1016/j.yexcr.2022.113442_bib111) 2013; 756 Singh (10.1016/j.yexcr.2022.113442_bib7) 1998; 63 Elmen (10.1016/j.yexcr.2022.113442_bib58) 2005; 33 Kauppinen (10.1016/j.yexcr.2022.113442_bib96) 2005; 2 Matsubara (10.1016/j.yexcr.2022.113442_bib131) 2007; 26 Di Giusto (10.1016/j.yexcr.2022.113442_bib17) 2004; 32 Troels Koch (10.1016/j.yexcr.2022.113442_bib30) 2001 Gullà (10.1016/j.yexcr.2022.113442_bib127) 2016; 22 Ahmadi (10.1016/j.yexcr.2022.113442_bib88) 2016; 23 Veedu (10.1016/j.yexcr.2022.113442_bib26) 2009; 6 Sutani (10.1016/j.yexcr.2022.113442_bib109) 2006; 95 Wu (10.1016/j.yexcr.2022.113442_bib98) 2019; 10 Jepsen (10.1016/j.yexcr.2022.113442_bib18) 2004; 14 Obad (10.1016/j.yexcr.2022.113442_bib63) 2011; 43 Stein (10.1016/j.yexcr.2022.113442_bib49) 2010; 38 Breitenbuecher (10.1016/j.yexcr.2022.113442_bib123) 2014; 9 Chen (10.1016/j.yexcr.2022.113442_bib113) 2014; 406 Sørensen (10.1016/j.yexcr.2022.113442_bib44) 2002; 124 Yildirim (10.1016/j.yexcr.2022.113442_bib22) 2014; 118 Ugozzoli (10.1016/j.yexcr.2022.113442_bib114) 1991; 2 Torres (10.1016/j.yexcr.2022.113442_bib87) 2016; 16 |
| References_xml | – volume: 21 start-page: 74 year: 2003 end-page: 81 ident: bib9 article-title: LNA: a versatile tool for therapeutics and genomics publication-title: Trends Biotechnol. – volume: 406 start-page: 2477 year: 2014 end-page: 2487 ident: bib113 article-title: High-sensitivity PCR method for detecting BRAF V600E mutations in metastatic colorectal cancer using LNA/DNA chimeras to block wild-type alleles publication-title: Anal. Bioanal. Chem. – volume: 19 start-page: 5551 year: 1991 end-page: 5559 ident: bib46 article-title: Interactions of antisense DNa oliginucletide analogs with phospholid membranes (liposomes) publication-title: Nucleic Acids Res. – volume: 4 start-page: i year: 2007 end-page: ii ident: bib124 article-title: MicroRNA profiling of breast cancer tissue using an LNA-based microarray publication-title: Nat. Methods – volume: 54 start-page: 3607 year: 1998 end-page: 3630 ident: bib5 article-title: LNA (Locked Nucleic Acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition publication-title: Tetrahedron – volume: 7 year: 2017 ident: bib23 article-title: LNA effects on DNA binding and conformation: from single strand to duplex and triplex structures publication-title: Sci. Rep. – volume: 37 start-page: 2721 year: 2017 end-page: 2725 ident: bib110 article-title: EGFR T790M detection in circulating tumor DNA from non-small cell lung cancer patients using the PNA-LNA clamp method publication-title: Anticancer Res. – volume: 22 start-page: 1222 year: 2016 end-page: 1233 ident: bib127 article-title: A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells publication-title: Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res. – volume: 26 start-page: 1427 year: 2007 end-page: 1430 ident: bib91 article-title: Survivin mRNA antagonists using locked nucleic acid, potential for molecular cancer therapy publication-title: Nucleosides Nucleot. Nucleic Acids – volume: 6 start-page: 321 year: 2009 end-page: 323 ident: bib26 article-title: Locked nucleic acid as a novel class of therapeutic agents publication-title: RNA Biol. – volume: 33 start-page: 439 year: 2005 end-page: 447 ident: bib58 article-title: Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality publication-title: Nucleic Acids Res. – volume: 38 start-page: 8735 year: 1997 end-page: 8738 ident: bib12 article-title: Synthesis of 2′-O,4′-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3, -endo sugar puckering publication-title: Tetrahedron Lett. – volume: 18 start-page: 89 year: 2008 end-page: 102 ident: bib67 article-title: The utility of LNA in microRNA-based cancer diagnostics and therapeutics publication-title: Semin. Cancer Biol. – volume: 26 start-page: 731 year: 2007 end-page: 743 ident: bib130 article-title: Transcriptional activation of miR-34a contributes to p53-mediated apoptosis publication-title: Mol. Cell. – volume: 14 start-page: 1138 year: 2008 end-page: 1142 ident: bib54 article-title: Locked nucleic acid holds promise in the treatment of cancer publication-title: Curr. Pharmaceut. Des. – volume: 35 start-page: 687 year: 2007 end-page: 700 ident: bib100 article-title: Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals publication-title: Nucleic Acids Res. – volume: 22 start-page: 79 year: 2003 end-page: 85 ident: bib115 article-title: Enhanced allele-specific PCR discrimination in SNP genotyping using 3' locked nucleic acid (LNA) primers publication-title: Hum. Mutat. – volume: 12 year: 2019 ident: bib81 article-title: Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 publication-title: Cancers – volume: 63 start-page: 6078 year: 1998 end-page: 6079 ident: bib7 article-title: Synthesis of novel bicyclo[2.2.1] ribonucleosides: 2‘-amino- and 2‘-thio-LNA monomeric nucleosides publication-title: J. Org. Chem. – reference: Dumble ML, Zhang Y, Zhu P, Kim S, Qu Z, Shi V, et al., editors. 53 Down Regulation of Beta-Catenin by a Locked Nucleic Acid Oligonucleotide Antagonist Inhibits Tumor Growth in Experimental Models of Human Cancer2010. – volume: 154 start-page: 520 year: 2016 end-page: 525 ident: bib118 article-title: Direct detection of circulating free DNA extracted from serum samples of breast cancer using locked nucleic acid molecular beacon publication-title: Talanta – volume: 9 year: 2014 ident: bib123 article-title: Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients publication-title: PLoS One – volume: 13 start-page: 909 year: 2018 end-page: 914 ident: bib70 article-title: Targeting of G-quadruplex harboring pre-miRNA 92b by LNA rescues PTEN expression in NSCL cancer cells publication-title: ACS Chem. Biol. – volume: 8 start-page: 1 year: 2001 end-page: 7 ident: bib8 article-title: Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA publication-title: Chem. Biol. – start-page: 455 year: 1998 end-page: 456 ident: bib3 article-title: LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition publication-title: Chem. Commun. – volume: 20 start-page: 1099 year: 2016 end-page: 1108 ident: bib83 article-title: Mir-221/222 are promising targets for innovative anticancer therapy publication-title: Expert Opin. Ther. Targets – volume: 39 year: 2017 ident: bib75 article-title: Inhibition of microRNA-21 via locked nucleic acid-anti-miR suppressed metastatic features of colorectal cancer cells through modulation of programmed cell death 4 publication-title: Tumour. Biol. – volume: 14 start-page: 65 year: 2004 end-page: 74 ident: bib59 article-title: Modification of alternative splicing by antisense therapeutics publication-title: Oligonucleotides – volume: 454 start-page: 765 year: 2013 end-page: 774 ident: bib76 article-title: Silencing of miR-21 by locked nucleic acid-lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell death publication-title: Int. J. Pharm. – volume: 120 start-page: 1678 year: 2012 end-page: 1686 ident: bib65 article-title: LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas publication-title: Blood – volume: 16 start-page: 541 year: 2020 end-page: 556 ident: bib69 article-title: Delivery of LNA-antimiR-142-3p by mesenchymal stem cells-derived exosomes to breast cancer stem cells reduces tumorigenicity publication-title: Stem Cell. Rev. Rep. – volume: 825 start-page: 303 year: 2014 end-page: 352 ident: bib32 article-title: Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects publication-title: Adv. Exp. Med. Biol. – year: 2001 ident: bib30 article-title: Inventor; Roche Innovation Center Copenhagen AS, assignee. PROCESS FOR THE PREPARATION OF LNA PHOSPHORAMIDITE – volume: 30 start-page: 920 year: 2012 end-page: 923 ident: bib42 article-title: Assessing unintended hybridization-induced biological effects of oligonucleotides publication-title: Nat. Biotechnol. – volume: 41 start-page: 4049 year: 2013 end-page: 4064 ident: bib66 article-title: MAZ-binding G4-decoy with locked nucleic acid and twisted intercalating nucleic acid modifications suppresses KRAS in pancreatic cancer cells and delays tumor growth in mice publication-title: Nucleic Acids Res. – volume: 37 start-page: 94 year: 2018 ident: bib86 article-title: miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling publication-title: J. Exp. Clin. Cancer Res. : CR (Clim. Res.) – volume: 83 start-page: 53 year: 2018 end-page: 72 ident: bib14 article-title: Locked nucleic acid technology for highly sensitive detection of somatic mutations in cancer publication-title: Adv. Clin. Chem. – year: 2010 ident: bib47 article-title: The Biological Effect of an Antisense Oligonucleotide Depends on its Route of Endocytosis and Trafficking – volume: 18 start-page: 1365 year: 2006 end-page: 1370 ident: bib4 article-title: Lna (locked nucleic acid) publication-title: Nucleos Nucleot. – start-page: 1247 year: 1998 end-page: 1248 ident: bib13 article-title: Universality of LNA-mediated high-affinity nucleic acid recognition publication-title: Chem. Commun. – volume: 51 start-page: 9499 year: 2015 end-page: 9502 ident: bib106 article-title: Targeting VEGF with LNA-stabilized G-rich oligonucleotide for efficient breast cancer inhibition publication-title: Chem. Commun. – volume: 756 start-page: 321 year: 2013 end-page: 331 ident: bib111 article-title: Reliable detection of rare mutations in EGFR gene codon L858 by PNA-LNA PCR clamp in non-small cell lung cancer publication-title: Adv. Exp. Med. Biol. – volume: 3 start-page: 9 year: 2011 ident: bib2 article-title: Epigenetic changes in cancer publication-title: F1000 Biol. Rep. – volume: 43 start-page: 371 year: 2011 end-page: 378 ident: bib63 article-title: Silencing of microRNA families by seed-targeting tiny LNAs publication-title: Nat. Genet. – volume: 97 start-page: 5633 year: 2000 end-page: 5638 ident: bib43 article-title: Potent and nontoxic antisense oligonucleotides containing locked nucleic acids publication-title: Proc. Natl. Acad. Sci. USA – year: 2013 ident: bib31 article-title: Viridian Therapeutics Inc, Assignee. Oligonucleotide-Based Inhibitors Comprising Locked Nucleic Acid Motif – volume: 25 start-page: 317 year: 2015 end-page: 322 ident: bib105 article-title: Targeting cancer cells using LNA-modified aptamer-siRNA chimeras publication-title: Nucleic Acid Therapeut. – reference: Bandaru R, Zhao J, Richards M, Wu D, Xia J, Zhao H, et al. Novel Releasable PEG-Conjugates of LNA Antisense Oligonucleotides as Potent mRNA Antagonists to Cancer Targets. – volume: 26 start-page: 6099 year: 2007 end-page: 6105 ident: bib131 article-title: Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92 publication-title: Oncogene – volume: 5 year: 2016 ident: bib80 article-title: Pharmacokinetics and pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in mice and non-human primates publication-title: Mol. Ther. Nucleic Acids – volume: 118 start-page: 14177 year: 2014 end-page: 14187 ident: bib22 article-title: Interplay of LNA and 2'-O-methyl RNA in the structure and thermodynamics of RNA hybrid systems: a molecular dynamics study using the revised AMBER force field and comparison with experimental results publication-title: J. Phys. Chem. B – volume: 233 start-page: 509 year: 1993 end-page: 523 ident: bib38 article-title: Structure of a DNA:RNA hybrid duplex. Why RNase H does not cleave pure RNA publication-title: J. Mol. Biol. – volume: 23 start-page: 101 year: 2018 end-page: 114 ident: bib25 article-title: Locked nucleic acid: modality, diversity, and drug discovery publication-title: Drug Discov. Today – volume: 15 start-page: 338 year: 2018 end-page: 352 ident: bib62 article-title: Anti-miRNA oligonucleotides: a comprehensive guide for design publication-title: RNA Biol. – volume: 124 start-page: 2164 year: 2002 end-page: 2176 ident: bib44 article-title: α-l-ribo-Configured locked nucleic acid (α-L-LNA): synthesis and properties publication-title: J. Am. Chem. Soc. – volume: 8 start-page: 66 year: 2004 ident: bib94 article-title: 216 SPC-2004—a potent locked nucleic acid drug against Bcl-2 in cancer publication-title: EJC Suppl. – volume: 406 start-page: 131 year: 2014 end-page: 136 ident: bib112 article-title: Common consensus LNA probe for quantitative PCR assays in cancer: vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas publication-title: J. Immunol. Methods – volume: 188 year: 2020 ident: bib78 article-title: Development and validation of bioanalytical methods for LNA-i-miR-221 quantification in human plasma and urine by LC-MS/MS publication-title: J. Pharmaceut. Biomed. Anal. – volume: 73 start-page: 3486 year: 2013 ident: bib120 article-title: Abstract 3486: detection of AR W741 mutation in circulating tumor DNA from plasma samples of castration-resistant prostate cancer patients using LNA clamp-mediated PCR publication-title: Cancer Res. – volume: 134 start-page: 748 year: 2008 ident: bib121 article-title: W1985 MicroRNA expression profiling of colorectal cancer and its precancerous lesions using Lna™ oligonucleotide arrays publication-title: Gastroenterology – volume: 20 start-page: 384 year: 2020 ident: bib72 article-title: Therapeutic inhibition of microRNA-21 (miR-21) using locked-nucleic acid (LNA)-anti-miR and its effects on the biological behaviors of melanoma cancer cells in preclinical studies publication-title: Cancer Cell Int. – volume: 173 start-page: 405 year: 2006 end-page: 422 ident: bib97 article-title: Locked nucleic acid: high-affinity targeting of complementary RNA for RNomics publication-title: Handb. Exp. Pharmacol. – volume: 23 start-page: 199 year: 2016 end-page: 205 ident: bib88 article-title: Locked nucleic acid inhibits miR-92a-3p in human colorectal cancer, induces apoptosis and inhibits cell proliferation publication-title: Cancer Gene Ther. – volume: 76 start-page: A20 year: 2016 end-page: A ident: bib89 article-title: Abstract A20: innovative drug discovery for bladder cancer by miR-130 family seed-targeting locked nucleic acid publication-title: Cancer Res. – volume: 13 start-page: R2 year: 2011 ident: bib64 article-title: Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth publication-title: Breast Cancer Res. – volume: 37 start-page: 1022 year: 2009 end-page: 1026 ident: bib50 article-title: Dissecting dynamin's role in clathrin-mediated endocytosis publication-title: Biochem. Soc. Trans. – volume: 276 start-page: 1494 year: 2009 end-page: 1505 ident: bib40 article-title: Ribonuclease H: the enzymes in eukaryotes publication-title: FEBS J. – volume: 9 year: 2014 ident: bib79 article-title: In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells publication-title: PLoS One – volume: 14 start-page: 130 year: 2004 end-page: 146 ident: bib18 article-title: Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology publication-title: Oligonucleotides – volume: 12 start-page: 103 year: 2002 end-page: 128 ident: bib48 article-title: Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action publication-title: Antisense Nucleic Acid Drug Dev. – volume: 69 start-page: 57 year: 2020 end-page: 67 ident: bib101 article-title: A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression publication-title: Cancer Immunol. Immunother. – volume: 15 start-page: 4009 year: 2009 end-page: 4016 ident: bib74 article-title: Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development publication-title: Clin. Cancer Res. – volume: 109 start-page: 2579 year: 2013 end-page: 2586 ident: bib92 article-title: First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer publication-title: Br. J. Cancer – volume: 573 year: 2020 ident: bib68 article-title: Antisense LNA-loaded nanoparticles of star-shaped glucose-core PCL-PEG copolymer for enhanced inhibition of oncomiR-214 and nucleolin-mediated therapy of cisplatin-resistant ovarian cancer cells publication-title: Int. J. Pharm. – volume: 24 start-page: 81 year: 2005 end-page: 87 ident: bib57 article-title: Engineering genomics. RNA antagonists--a new class of antisense drugs publication-title: IEEE Eng. Med. Biol. Mag. – volume: 19 start-page: 6 year: 2018 ident: bib82 article-title: Targeting miR-9 in gastric cancer cells using locked nucleic acid oligonucleotides publication-title: BMC Mol. Biol. – volume: 18 start-page: 1519 year: 2013 end-page: 1526 ident: bib107 article-title: Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer publication-title: Mol. Med. – volume: 45 start-page: 2262 year: 2017 end-page: 2282 ident: bib41 article-title: Managing the sequence-specificity of antisense oligonucleotides in drug discovery publication-title: Nucleic Acids Res. – volume: 279 start-page: 17181 year: 2004 end-page: 17189 ident: bib37 article-title: Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs publication-title: J. Biol. Chem. – volume: 87 start-page: 104 year: 2015 end-page: 107 ident: bib33 article-title: Exon skipping therapy for Duchenne muscular dystrophy publication-title: Adv. Drug Deliv. Rev. – volume: 14 start-page: 5445 year: 2015 end-page: 5451 ident: bib99 article-title: Blocking the expression of the hepatitis B virus S gene in hepatocellular carcinoma cell lines with an anti-gene locked nucleic acid in vitro publication-title: Genet. Mol. Res. – volume: 43 start-page: 13233 year: 2004 end-page: 13241 ident: bib10 article-title: LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA publication-title: Biochemistry – volume: 30 start-page: 5160 year: 2002 end-page: 5167 ident: bib55 article-title: Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design publication-title: Nucleic Acids Res. – volume: 30 start-page: 2435 year: 2002 end-page: 2443 ident: bib45 article-title: Design and characterization of decoy oligonucleotides containing locked nucleic acids publication-title: Nucleic Acids Res. – volume: 10 start-page: 149 year: 2019 end-page: 160 ident: bib98 article-title: Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1alpha in advanced hepatocellular carcinoma publication-title: World J. Clin. Oncol. – volume: 2348 start-page: 123 year: 2021 end-page: 137 ident: bib132 article-title: Detection of lncRNA by LNA-based in situ hybridization in paraffin-embedded cancer cell spheroids publication-title: Methods Mol. Biol. – year: 2005 ident: bib104 publication-title: Pegylated-liposomal Formulation of Chimeric LNA/DNA Antisense Oligonucleotides against DNA MeTase and Vinorelbine Induces Apoptosis in Anaplastic Thyroid Cancer Characterised by 5 – volume: 12 start-page: 4194 year: 2018 end-page: 4205 ident: bib116 article-title: Single locked nucleic acid-enhanced nanopore genetic discrimination of pathogenic serotypes and cancer driver mutations publication-title: ACS Nano – volume: 6 year: 2016 ident: bib51 article-title: GapmeR cellular internalization by macropinocytosis induces sequence-specific gene silencing in human primary T-cells publication-title: Sci. Rep. – volume: 43 start-page: 9350 year: 2015 end-page: 9361 ident: bib39 article-title: A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells publication-title: Nucleic Acids Res. – year: 2012 ident: bib28 article-title: Locked Nucleic Acid Reagents for Labelling Nucleic Acids – volume: 282 start-page: 23716 year: 2007 end-page: 23724 ident: bib128 article-title: miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1 publication-title: J. Biol. Chem. – volume: 1 start-page: S212 year: 2003 end-page: S213 ident: bib56 article-title: 706 in vitro and in vivo efficacy of a HIF-1alpha-antisense oligonucleotide containing locked nucleic acids publication-title: Eur. J. Cancer Suppl. – volume: 7 year: 2016 ident: bib34 article-title: Activating frataxin expression by repeat-targeted nucleic acids publication-title: Nat. Commun. – volume: 88 start-page: 8237 year: 1991 end-page: 8241 ident: bib52 article-title: Rapid renaturation of complementary DNA strands mediated by cationic detergents: a role for high-probability binding domains in enhancing the kinetics of molecular assembly processes publication-title: Proc. Natl. Acad. Sci. USA – volume: 327 start-page: 198 year: 2010 end-page: 201 ident: bib36 article-title: Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection publication-title: Science – volume: 14 start-page: 942 year: 2004 end-page: 950 ident: bib1 article-title: The Ensembl automatic gene annotation system publication-title: Genome Res. – volume: 117 start-page: 5556 year: 2013 end-page: 5564 ident: bib21 article-title: Structures, dynamics, and stabilities of fully modified locked nucleic acid (beta-D-LNA and alpha-L-LNA) duplexes in comparison to pure DNA and RNA duplexes publication-title: J. Phys. Chem. B – start-page: 519 year: 2007 end-page: 564 ident: bib16 article-title: Locked nucleic acid publication-title: Antisense Drug Technol. – volume: 21 start-page: 235 year: 2007 end-page: 243 ident: bib27 article-title: Locked nucleic acid oligonucleotides: the next generation of antisense agents? publication-title: BioDrugs : Clin. Immunotherapeut. Biopharmaceut. Gene Ther. – volume: 16 start-page: 822 year: 2016 ident: bib87 article-title: In vitro and in vivo activity of miR-92a–Locked Nucleic Acid (LNA)–Inhibitor against endometrial cancer publication-title: BMC Cancer – volume: 95 start-page: 1483 year: 2006 end-page: 1489 ident: bib109 article-title: Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp publication-title: Br. J. Cancer – volume: 65 start-page: 7276 year: 2005 end-page: 7282 ident: bib108 article-title: Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp publication-title: Cancer Res. – volume: 67 start-page: 1776 year: 2007 ident: bib125 article-title: Global microRNA profiling of the NCI-60 cancer cell lines using novel locked nucleic acid (LNA) based technologies publication-title: Cancer Res. – volume: 30 start-page: 1911 year: 2002 end-page: 1918 ident: bib20 article-title: Design of antisense oligonucleotides stabilized by locked nucleic acids publication-title: Nucleic Acids Res. – volume: 6 start-page: 851 year: 2014 end-page: 864 ident: bib35 article-title: Development of microRNA therapeutics is coming of age publication-title: EMBO Mol. Med. – volume: 88 start-page: 8902 year: 2016 end-page: 8907 ident: bib117 article-title: Probing 3D collective cancer invasion using double-stranded locked nucleic acid biosensors publication-title: Anal. Chem. – volume: 16 start-page: 494 year: 1999 end-page: 502 ident: bib53 article-title: Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides publication-title: Pharmaceut. Res. – volume: 39 start-page: 4381 year: 1998 end-page: 4384 ident: bib11 article-title: Novel convenient syntheses of LNA [2.2.1]bicyclo nucleosides publication-title: Tetrahedron Lett. – volume: 41 start-page: 9973 year: 2002 end-page: 9981 ident: bib95 article-title: Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase publication-title: Biochemistry – volume: 132 start-page: 1050 year: 2018 end-page: 1063 ident: bib85 article-title: Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 publication-title: Blood – volume: 309 start-page: 310 year: 2005 end-page: 311 ident: bib126 article-title: MicroRNA expression in zebrafish embryonic development publication-title: Science – volume: 32 start-page: e32 year: 2004 ident: bib17 article-title: Strong positional preference in the interaction of LNA oligonucleotides with DNA polymerase and proofreading exonuclease activities: implications for genotyping assays publication-title: Nucleic Acids Res. – volume: 2 start-page: 287 year: 2005 end-page: 290 ident: bib96 article-title: Locked nucleic acid (LNA): high affinity targeting of RNA for diagnostics and therapeutics publication-title: Drug Discov. Today Technol. – volume: 36 start-page: 1083 year: 2016 end-page: 1088 ident: bib73 article-title: Locked nucleic acid in situ hybridization analysis of MicroRNA-21 predicts clinical outcome in patients after resection for pancreatic cancer treated with adjuvant gemcitabine monotherapy publication-title: Anticancer Res. – volume: 27 start-page: 2240 year: 2007 end-page: 2252 ident: bib129 article-title: Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression publication-title: Mol. Cell Biol. – volume: 18 start-page: 326 year: 2011 end-page: 333 ident: bib90 article-title: Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection publication-title: Gene Ther. – volume: 15 start-page: 449 year: 2004 end-page: 457 ident: bib6 article-title: NMR studies of fully modified locked nucleic acid (LNA) hybrids: solution structure of an LNA:RNA hybrid and characterization of an LNA:DNA hybrid publication-title: Bioconjugate Chem. – volume: 457 start-page: 75 year: 2016 end-page: 80 ident: bib122 article-title: Locked nucleic acid probe enhances Sanger sequencing sensitivity and improves diagnostic accuracy of high-resolution melting-based KRAS mutational analysis publication-title: Clin. Chim. Acta – reference: Mads Detlef Sorensen JW, Troels Koch, Signe M. Christensen, Christoph Rosenbohm, Daniel Sejer Pedersen, Inventor; roche innovation center copenhagen AS, assignee. Synth. Locked Nucleic Acid Deriv.. Canada 2003. – volume: 2 start-page: 42 year: 1991 end-page: 48 ident: bib114 article-title: Allele-specific polymerase chain reaction publication-title: Methods – volume: 14 year: 2019 ident: bib24 article-title: The ability of locked nucleic acid oligonucleotides to pre-structure the double helix: a molecular simulation and binding study publication-title: PLoS One – volume: 71 start-page: 8 year: 2016 end-page: 16 ident: bib61 article-title: Chemical modification of nucleic acids as a key technology for the development of RNA-based therapeutics publication-title: Pharmazie – volume: 20 start-page: 389 year: 2001 end-page: 396 ident: bib15 article-title: LNA (locked nucleic acid) and the diastereoisomeric alpha-L-LNA: conformational tuning and high-affinity recognition of DNA/RNA targets publication-title: Nucleosides Nucleot. Nucleic Acids – volume: 27 start-page: 1139 year: 2021 end-page: 1149 ident: bib71 article-title: Cobomarsen, an oligonucleotide inhibitor of miR-155, slows DLBCL tumor cell growth in vitro and in vivo publication-title: Clin. Cancer Res. – volume: 7 start-page: 73651 year: 2016 end-page: 73663 ident: bib77 article-title: Locked nucleic acid-inhibitor of miR-205 decreases endometrial cancer cells proliferation in vitro and in vivo publication-title: Oncotarget – volume: 4 start-page: 242 year: 2013 end-page: 255 ident: bib84 article-title: In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma publication-title: Oncotarget – volume: 109 start-page: 2579 year: 2013 end-page: 2586 ident: bib102 article-title: First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer publication-title: Br. J. Cancer – volume: 38 start-page: e3 year: 2010 end-page: e ident: bib49 article-title: Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents publication-title: Nucleic Acids Res. – volume: 31 start-page: 6365 year: 2003 end-page: 6372 ident: bib19 article-title: Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA publication-title: Nucleic Acids Res. – volume: 17 start-page: 1169 year: 2011 end-page: 1180 ident: bib119 article-title: Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay publication-title: Clin. Cancer Res. – volume: 14 start-page: 471 year: 2006 end-page: 475 ident: bib60 article-title: Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice publication-title: Mol. Ther. – volume: 2348 start-page: 123 year: 2021 ident: 10.1016/j.yexcr.2022.113442_bib132 article-title: Detection of lncRNA by LNA-based in situ hybridization in paraffin-embedded cancer cell spheroids publication-title: Methods Mol. Biol. doi: 10.1007/978-1-0716-1581-2_8 – volume: 38 start-page: e3 issue: 1 year: 2010 ident: 10.1016/j.yexcr.2022.113442_bib49 article-title: Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkp841 – volume: 8 start-page: 66 issue: 2 year: 2004 ident: 10.1016/j.yexcr.2022.113442_bib94 article-title: 216 SPC-2004—a potent locked nucleic acid drug against Bcl-2 in cancer publication-title: EJC Suppl. doi: 10.1016/S1359-6349(04)80224-6 – volume: 69 start-page: 57 issue: 1 year: 2020 ident: 10.1016/j.yexcr.2022.113442_bib101 article-title: A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-019-02438-1 – volume: 36 start-page: 1083 issue: 3 year: 2016 ident: 10.1016/j.yexcr.2022.113442_bib73 article-title: Locked nucleic acid in situ hybridization analysis of MicroRNA-21 predicts clinical outcome in patients after resection for pancreatic cancer treated with adjuvant gemcitabine monotherapy publication-title: Anticancer Res. – volume: 67 start-page: 1776 issue: 9_Supplement year: 2007 ident: 10.1016/j.yexcr.2022.113442_bib125 article-title: Global microRNA profiling of the NCI-60 cancer cell lines using novel locked nucleic acid (LNA) based technologies publication-title: Cancer Res. – volume: 276 start-page: 1494 issue: 6 year: 2009 ident: 10.1016/j.yexcr.2022.113442_bib40 article-title: Ribonuclease H: the enzymes in eukaryotes publication-title: FEBS J. doi: 10.1111/j.1742-4658.2009.06908.x – volume: 14 issue: 2 year: 2019 ident: 10.1016/j.yexcr.2022.113442_bib24 article-title: The ability of locked nucleic acid oligonucleotides to pre-structure the double helix: a molecular simulation and binding study publication-title: PLoS One doi: 10.1371/journal.pone.0211651 – volume: 87 start-page: 104 year: 2015 ident: 10.1016/j.yexcr.2022.113442_bib33 article-title: Exon skipping therapy for Duchenne muscular dystrophy publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2015.05.008 – volume: 10 start-page: 149 issue: 3 year: 2019 ident: 10.1016/j.yexcr.2022.113442_bib98 article-title: Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1alpha in advanced hepatocellular carcinoma publication-title: World J. Clin. Oncol. doi: 10.5306/wjco.v10.i3.149 – volume: 51 start-page: 9499 issue: 46 year: 2015 ident: 10.1016/j.yexcr.2022.113442_bib106 article-title: Targeting VEGF with LNA-stabilized G-rich oligonucleotide for efficient breast cancer inhibition publication-title: Chem. Commun. doi: 10.1039/C5CC02756J – volume: 27 start-page: 2240 issue: 6 year: 2007 ident: 10.1016/j.yexcr.2022.113442_bib129 article-title: Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression publication-title: Mol. Cell Biol. doi: 10.1128/MCB.02005-06 – volume: 30 start-page: 920 issue: 10 year: 2012 ident: 10.1016/j.yexcr.2022.113442_bib42 article-title: Assessing unintended hybridization-induced biological effects of oligonucleotides publication-title: Nat. Biotechnol. doi: 10.1038/nbt.2376 – year: 2001 ident: 10.1016/j.yexcr.2022.113442_bib30 – volume: 54 start-page: 3607 issue: 14 year: 1998 ident: 10.1016/j.yexcr.2022.113442_bib5 article-title: LNA (Locked Nucleic Acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition publication-title: Tetrahedron doi: 10.1016/S0040-4020(98)00094-5 – volume: 83 start-page: 53 year: 2018 ident: 10.1016/j.yexcr.2022.113442_bib14 article-title: Locked nucleic acid technology for highly sensitive detection of somatic mutations in cancer publication-title: Adv. Clin. Chem. doi: 10.1016/bs.acc.2017.10.002 – volume: 14 start-page: 65 issue: 1 year: 2004 ident: 10.1016/j.yexcr.2022.113442_bib59 article-title: Modification of alternative splicing by antisense therapeutics publication-title: Oligonucleotides doi: 10.1089/154545704322988067 – volume: 35 start-page: 687 issue: 2 year: 2007 ident: 10.1016/j.yexcr.2022.113442_bib100 article-title: Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkl1071 – volume: 19 start-page: 5551 issue: 20 year: 1991 ident: 10.1016/j.yexcr.2022.113442_bib46 article-title: Interactions of antisense DNa oliginucletide analogs with phospholid membranes (liposomes) publication-title: Nucleic Acids Res. doi: 10.1093/nar/19.20.5551 – volume: 12 start-page: 103 issue: 2 year: 2002 ident: 10.1016/j.yexcr.2022.113442_bib48 article-title: Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action publication-title: Antisense Nucleic Acid Drug Dev. doi: 10.1089/108729002760070849 – volume: 756 start-page: 321 year: 2013 ident: 10.1016/j.yexcr.2022.113442_bib111 article-title: Reliable detection of rare mutations in EGFR gene codon L858 by PNA-LNA PCR clamp in non-small cell lung cancer publication-title: Adv. Exp. Med. Biol. doi: 10.1007/978-94-007-4549-0_39 – year: 2010 ident: 10.1016/j.yexcr.2022.113442_bib47 – volume: 279 start-page: 17181 issue: 17 year: 2004 ident: 10.1016/j.yexcr.2022.113442_bib37 article-title: Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs publication-title: J. Biol. Chem. doi: 10.1074/jbc.M311683200 – volume: 327 start-page: 198 issue: 5962 year: 2010 ident: 10.1016/j.yexcr.2022.113442_bib36 article-title: Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection publication-title: Science doi: 10.1126/science.1178178 – volume: 109 start-page: 2579 issue: 10 year: 2013 ident: 10.1016/j.yexcr.2022.113442_bib102 article-title: First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer publication-title: Br. J. Cancer doi: 10.1038/bjc.2013.619 – year: 2013 ident: 10.1016/j.yexcr.2022.113442_bib31 – volume: 95 start-page: 1483 issue: 11 year: 2006 ident: 10.1016/j.yexcr.2022.113442_bib109 article-title: Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp publication-title: Br. J. Cancer doi: 10.1038/sj.bjc.6603466 – volume: 88 start-page: 8237 issue: 18 year: 1991 ident: 10.1016/j.yexcr.2022.113442_bib52 article-title: Rapid renaturation of complementary DNA strands mediated by cationic detergents: a role for high-probability binding domains in enhancing the kinetics of molecular assembly processes publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.88.18.8237 – volume: 33 start-page: 439 issue: 1 year: 2005 ident: 10.1016/j.yexcr.2022.113442_bib58 article-title: Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality publication-title: Nucleic Acids Res. doi: 10.1093/nar/gki193 – volume: 16 start-page: 494 issue: 4 year: 1999 ident: 10.1016/j.yexcr.2022.113442_bib53 article-title: Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides publication-title: Pharmaceut. Res. doi: 10.1023/A:1011958726518 – volume: 406 start-page: 131 year: 2014 ident: 10.1016/j.yexcr.2022.113442_bib112 article-title: Common consensus LNA probe for quantitative PCR assays in cancer: vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2014.03.004 – volume: 30 start-page: 5160 issue: 23 year: 2002 ident: 10.1016/j.yexcr.2022.113442_bib55 article-title: Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkf651 – volume: 13 start-page: R2 issue: 1 year: 2011 ident: 10.1016/j.yexcr.2022.113442_bib64 article-title: Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth publication-title: Breast Cancer Res. doi: 10.1186/bcr2803 – volume: 14 start-page: 942 issue: 5 year: 2004 ident: 10.1016/j.yexcr.2022.113442_bib1 article-title: The Ensembl automatic gene annotation system publication-title: Genome Res. doi: 10.1101/gr.1858004 – volume: 41 start-page: 4049 issue: 7 year: 2013 ident: 10.1016/j.yexcr.2022.113442_bib66 article-title: MAZ-binding G4-decoy with locked nucleic acid and twisted intercalating nucleic acid modifications suppresses KRAS in pancreatic cancer cells and delays tumor growth in mice publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkt127 – volume: 14 start-page: 471 issue: 4 year: 2006 ident: 10.1016/j.yexcr.2022.113442_bib60 article-title: Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice publication-title: Mol. Ther. doi: 10.1016/j.ymthe.2006.05.017 – ident: 10.1016/j.yexcr.2022.113442_bib103 – volume: 16 start-page: 541 issue: 3 year: 2020 ident: 10.1016/j.yexcr.2022.113442_bib69 article-title: Delivery of LNA-antimiR-142-3p by mesenchymal stem cells-derived exosomes to breast cancer stem cells reduces tumorigenicity publication-title: Stem Cell. Rev. Rep. doi: 10.1007/s12015-019-09944-w – volume: 20 start-page: 1099 issue: 9 year: 2016 ident: 10.1016/j.yexcr.2022.113442_bib83 article-title: Mir-221/222 are promising targets for innovative anticancer therapy publication-title: Expert Opin. Ther. Targets doi: 10.1517/14728222.2016.1164693 – volume: 43 start-page: 9350 issue: 19 year: 2015 ident: 10.1016/j.yexcr.2022.113442_bib39 article-title: A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkv964 – volume: 18 start-page: 89 issue: 2 year: 2008 ident: 10.1016/j.yexcr.2022.113442_bib67 article-title: The utility of LNA in microRNA-based cancer diagnostics and therapeutics publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2008.01.004 – volume: 132 start-page: 1050 issue: 10 year: 2018 ident: 10.1016/j.yexcr.2022.113442_bib85 article-title: Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 publication-title: Blood doi: 10.1182/blood-2018-03-836601 – volume: 43 start-page: 13233 issue: 42 year: 2004 ident: 10.1016/j.yexcr.2022.113442_bib10 article-title: LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA publication-title: Biochemistry doi: 10.1021/bi0485732 – volume: 39 issue: 3 year: 2017 ident: 10.1016/j.yexcr.2022.113442_bib75 article-title: Inhibition of microRNA-21 via locked nucleic acid-anti-miR suppressed metastatic features of colorectal cancer cells through modulation of programmed cell death 4 publication-title: Tumour. Biol. doi: 10.1177/1010428317692261 – volume: 31 start-page: 6365 issue: 21 year: 2003 ident: 10.1016/j.yexcr.2022.113442_bib19 article-title: Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkg820 – volume: 16 start-page: 822 issue: 1 year: 2016 ident: 10.1016/j.yexcr.2022.113442_bib87 article-title: In vitro and in vivo activity of miR-92a–Locked Nucleic Acid (LNA)–Inhibitor against endometrial cancer publication-title: BMC Cancer doi: 10.1186/s12885-016-2867-z – year: 2012 ident: 10.1016/j.yexcr.2022.113442_bib28 – volume: 18 start-page: 1365 issue: 6–7 year: 2006 ident: 10.1016/j.yexcr.2022.113442_bib4 article-title: Lna (locked nucleic acid) publication-title: Nucleos Nucleot. – volume: 17 start-page: 1169 issue: 5 year: 2011 ident: 10.1016/j.yexcr.2022.113442_bib119 article-title: Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-10-2277 – volume: 9 issue: 1 year: 2014 ident: 10.1016/j.yexcr.2022.113442_bib123 article-title: Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients publication-title: PLoS One doi: 10.1371/journal.pone.0085350 – volume: 41 start-page: 9973 issue: 31 year: 2002 ident: 10.1016/j.yexcr.2022.113442_bib95 article-title: Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase publication-title: Biochemistry doi: 10.1021/bi025907j – volume: 109 start-page: 2579 issue: 10 year: 2013 ident: 10.1016/j.yexcr.2022.113442_bib92 article-title: First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer publication-title: Br. J. Cancer doi: 10.1038/bjc.2013.619 – volume: 4 start-page: 242 issue: 2 year: 2013 ident: 10.1016/j.yexcr.2022.113442_bib84 article-title: In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma publication-title: Oncotarget doi: 10.18632/oncotarget.820 – volume: 2 start-page: 287 issue: 3 year: 2005 ident: 10.1016/j.yexcr.2022.113442_bib96 article-title: Locked nucleic acid (LNA): high affinity targeting of RNA for diagnostics and therapeutics publication-title: Drug Discov. Today Technol. doi: 10.1016/j.ddtec.2005.08.012 – start-page: 519 year: 2007 ident: 10.1016/j.yexcr.2022.113442_bib16 article-title: Locked nucleic acid publication-title: Antisense Drug Technol. doi: 10.1201/9780849387951.ch19 – volume: 20 start-page: 384 year: 2020 ident: 10.1016/j.yexcr.2022.113442_bib72 article-title: Therapeutic inhibition of microRNA-21 (miR-21) using locked-nucleic acid (LNA)-anti-miR and its effects on the biological behaviors of melanoma cancer cells in preclinical studies publication-title: Cancer Cell Int. doi: 10.1186/s12935-020-01394-6 – volume: 457 start-page: 75 year: 2016 ident: 10.1016/j.yexcr.2022.113442_bib122 article-title: Locked nucleic acid probe enhances Sanger sequencing sensitivity and improves diagnostic accuracy of high-resolution melting-based KRAS mutational analysis publication-title: Clin. Chim. Acta doi: 10.1016/j.cca.2016.04.005 – volume: 20 start-page: 389 issue: 4–7 year: 2001 ident: 10.1016/j.yexcr.2022.113442_bib15 article-title: LNA (locked nucleic acid) and the diastereoisomeric alpha-L-LNA: conformational tuning and high-affinity recognition of DNA/RNA targets publication-title: Nucleosides Nucleot. Nucleic Acids doi: 10.1081/NCN-100002312 – volume: 76 start-page: A20 issue: 6_Supplement year: 2016 ident: 10.1016/j.yexcr.2022.113442_bib89 article-title: Abstract A20: innovative drug discovery for bladder cancer by miR-130 family seed-targeting locked nucleic acid publication-title: Cancer Res. doi: 10.1158/1538-7445.NONRNA15-A20 – volume: 26 start-page: 1427 issue: 10–12 year: 2007 ident: 10.1016/j.yexcr.2022.113442_bib91 article-title: Survivin mRNA antagonists using locked nucleic acid, potential for molecular cancer therapy publication-title: Nucleosides Nucleot. Nucleic Acids doi: 10.1080/15257770701542132 – volume: 37 start-page: 1022 issue: Pt 5 year: 2009 ident: 10.1016/j.yexcr.2022.113442_bib50 article-title: Dissecting dynamin's role in clathrin-mediated endocytosis publication-title: Biochem. Soc. Trans. doi: 10.1042/BST0371022 – volume: 37 start-page: 94 issue: 1 year: 2018 ident: 10.1016/j.yexcr.2022.113442_bib86 article-title: miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling publication-title: J. Exp. Clin. Cancer Res. : CR (Clim. Res.) doi: 10.1186/s13046-018-0767-6 – volume: 73 start-page: 3486 issue: 8_Supplement year: 2013 ident: 10.1016/j.yexcr.2022.113442_bib120 article-title: Abstract 3486: detection of AR W741 mutation in circulating tumor DNA from plasma samples of castration-resistant prostate cancer patients using LNA clamp-mediated PCR publication-title: Cancer Res. doi: 10.1158/1538-7445.AM2013-3486 – volume: 24 start-page: 81 issue: 4 year: 2005 ident: 10.1016/j.yexcr.2022.113442_bib57 article-title: Engineering genomics. RNA antagonists--a new class of antisense drugs publication-title: IEEE Eng. Med. Biol. Mag. doi: 10.1109/MEMB.2005.1463401 – volume: 23 start-page: 101 issue: 1 year: 2018 ident: 10.1016/j.yexcr.2022.113442_bib25 article-title: Locked nucleic acid: modality, diversity, and drug discovery publication-title: Drug Discov. Today doi: 10.1016/j.drudis.2017.09.018 – volume: 6 year: 2016 ident: 10.1016/j.yexcr.2022.113442_bib51 article-title: GapmeR cellular internalization by macropinocytosis induces sequence-specific gene silencing in human primary T-cells publication-title: Sci. Rep. doi: 10.1038/srep37721 – volume: 37 start-page: 2721 issue: 5 year: 2017 ident: 10.1016/j.yexcr.2022.113442_bib110 article-title: EGFR T790M detection in circulating tumor DNA from non-small cell lung cancer patients using the PNA-LNA clamp method publication-title: Anticancer Res. doi: 10.21873/anticanres.11623 – volume: 26 start-page: 731 issue: 5 year: 2007 ident: 10.1016/j.yexcr.2022.113442_bib130 article-title: Transcriptional activation of miR-34a contributes to p53-mediated apoptosis publication-title: Mol. Cell. doi: 10.1016/j.molcel.2007.05.017 – volume: 97 start-page: 5633 issue: 10 year: 2000 ident: 10.1016/j.yexcr.2022.113442_bib43 article-title: Potent and nontoxic antisense oligonucleotides containing locked nucleic acids publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.97.10.5633 – volume: 120 start-page: 1678 issue: 8 year: 2012 ident: 10.1016/j.yexcr.2022.113442_bib65 article-title: LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas publication-title: Blood doi: 10.1182/blood-2012-02-410647 – volume: 134 start-page: 748 issue: 4 year: 2008 ident: 10.1016/j.yexcr.2022.113442_bib121 article-title: W1985 MicroRNA expression profiling of colorectal cancer and its precancerous lesions using Lna™ oligonucleotide arrays publication-title: Gastroenterology doi: 10.1016/S0016-5085(08)63492-7 – volume: 7 start-page: 73651 issue: 45 year: 2016 ident: 10.1016/j.yexcr.2022.113442_bib77 article-title: Locked nucleic acid-inhibitor of miR-205 decreases endometrial cancer cells proliferation in vitro and in vivo publication-title: Oncotarget doi: 10.18632/oncotarget.12043 – volume: 38 start-page: 8735 issue: 50 year: 1997 ident: 10.1016/j.yexcr.2022.113442_bib12 article-title: Synthesis of 2′-O,4′-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3, -endo sugar puckering publication-title: Tetrahedron Lett. doi: 10.1016/S0040-4039(97)10322-7 – volume: 39 start-page: 4381 issue: 24 year: 1998 ident: 10.1016/j.yexcr.2022.113442_bib11 article-title: Novel convenient syntheses of LNA [2.2.1]bicyclo nucleosides publication-title: Tetrahedron Lett. doi: 10.1016/S0040-4039(98)00706-0 – volume: 15 start-page: 449 issue: 3 year: 2004 ident: 10.1016/j.yexcr.2022.113442_bib6 article-title: NMR studies of fully modified locked nucleic acid (LNA) hybrids: solution structure of an LNA:RNA hybrid and characterization of an LNA:DNA hybrid publication-title: Bioconjugate Chem. doi: 10.1021/bc034145h – volume: 14 start-page: 1138 issue: 11 year: 2008 ident: 10.1016/j.yexcr.2022.113442_bib54 article-title: Locked nucleic acid holds promise in the treatment of cancer publication-title: Curr. Pharmaceut. Des. doi: 10.2174/138161208784246234 – volume: 71 start-page: 8 issue: 1 year: 2016 ident: 10.1016/j.yexcr.2022.113442_bib61 article-title: Chemical modification of nucleic acids as a key technology for the development of RNA-based therapeutics publication-title: Pharmazie – volume: 30 start-page: 1911 issue: 9 year: 2002 ident: 10.1016/j.yexcr.2022.113442_bib20 article-title: Design of antisense oligonucleotides stabilized by locked nucleic acids publication-title: Nucleic Acids Res. doi: 10.1093/nar/30.9.1911 – volume: 22 start-page: 79 issue: 1 year: 2003 ident: 10.1016/j.yexcr.2022.113442_bib115 article-title: Enhanced allele-specific PCR discrimination in SNP genotyping using 3' locked nucleic acid (LNA) primers publication-title: Hum. Mutat. doi: 10.1002/humu.10228 – volume: 23 start-page: 199 issue: 7 year: 2016 ident: 10.1016/j.yexcr.2022.113442_bib88 article-title: Locked nucleic acid inhibits miR-92a-3p in human colorectal cancer, induces apoptosis and inhibits cell proliferation publication-title: Cancer Gene Ther. doi: 10.1038/cgt.2016.10 – volume: 43 start-page: 371 issue: 4 year: 2011 ident: 10.1016/j.yexcr.2022.113442_bib63 article-title: Silencing of microRNA families by seed-targeting tiny LNAs publication-title: Nat. Genet. doi: 10.1038/ng.786 – volume: 18 start-page: 1519 issue: 1 year: 2013 ident: 10.1016/j.yexcr.2022.113442_bib107 article-title: Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer publication-title: Mol. Med. – volume: 14 start-page: 5445 issue: 2 year: 2015 ident: 10.1016/j.yexcr.2022.113442_bib99 article-title: Blocking the expression of the hepatitis B virus S gene in hepatocellular carcinoma cell lines with an anti-gene locked nucleic acid in vitro publication-title: Genet. Mol. Res. doi: 10.4238/2015.May.22.14 – year: 2005 ident: 10.1016/j.yexcr.2022.113442_bib104 – volume: 65 start-page: 7276 issue: 16 year: 2005 ident: 10.1016/j.yexcr.2022.113442_bib108 article-title: Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-05-0331 – volume: 7 issue: 1 year: 2017 ident: 10.1016/j.yexcr.2022.113442_bib23 article-title: LNA effects on DNA binding and conformation: from single strand to duplex and triplex structures publication-title: Sci. Rep. doi: 10.1038/s41598-017-09147-8 – ident: 10.1016/j.yexcr.2022.113442_bib93 doi: 10.1016/S1359-6349(10)71758-4 – volume: 63 start-page: 6078 issue: 18 year: 1998 ident: 10.1016/j.yexcr.2022.113442_bib7 article-title: Synthesis of novel bicyclo[2.2.1] ribonucleosides: 2‘-amino- and 2‘-thio-LNA monomeric nucleosides publication-title: J. Org. Chem. doi: 10.1021/jo9806658 – volume: 22 start-page: 1222 issue: 5 year: 2016 ident: 10.1016/j.yexcr.2022.113442_bib127 article-title: A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells publication-title: Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-15-0489 – volume: 19 start-page: 6 issue: 1 year: 2018 ident: 10.1016/j.yexcr.2022.113442_bib82 article-title: Targeting miR-9 in gastric cancer cells using locked nucleic acid oligonucleotides publication-title: BMC Mol. Biol. doi: 10.1186/s12867-018-0107-6 – volume: 12 start-page: 4194 issue: 5 year: 2018 ident: 10.1016/j.yexcr.2022.113442_bib116 article-title: Single locked nucleic acid-enhanced nanopore genetic discrimination of pathogenic serotypes and cancer driver mutations publication-title: ACS Nano doi: 10.1021/acsnano.8b01198 – volume: 21 start-page: 235 issue: 4 year: 2007 ident: 10.1016/j.yexcr.2022.113442_bib27 article-title: Locked nucleic acid oligonucleotides: the next generation of antisense agents? publication-title: BioDrugs : Clin. Immunotherapeut. Biopharmaceut. Gene Ther. doi: 10.2165/00063030-200721040-00004 – volume: 124 start-page: 2164 issue: 10 year: 2002 ident: 10.1016/j.yexcr.2022.113442_bib44 article-title: α-l-ribo-Configured locked nucleic acid (α-L-LNA): synthesis and properties publication-title: J. Am. Chem. Soc. doi: 10.1021/ja0168763 – volume: 454 start-page: 765 issue: 2 year: 2013 ident: 10.1016/j.yexcr.2022.113442_bib76 article-title: Silencing of miR-21 by locked nucleic acid-lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell death publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2013.05.049 – volume: 8 start-page: 1 issue: 1 year: 2001 ident: 10.1016/j.yexcr.2022.113442_bib8 article-title: Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA publication-title: Chem. Biol. doi: 10.1016/S1074-5521(00)00058-2 – volume: 45 start-page: 2262 issue: 5 year: 2017 ident: 10.1016/j.yexcr.2022.113442_bib41 article-title: Managing the sequence-specificity of antisense oligonucleotides in drug discovery publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkx056 – volume: 825 start-page: 303 year: 2014 ident: 10.1016/j.yexcr.2022.113442_bib32 article-title: Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects publication-title: Adv. Exp. Med. Biol. doi: 10.1007/978-1-4939-1221-6_9 – volume: 26 start-page: 6099 issue: 41 year: 2007 ident: 10.1016/j.yexcr.2022.113442_bib131 article-title: Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92 publication-title: Oncogene doi: 10.1038/sj.onc.1210425 – volume: 6 start-page: 321 issue: 3 year: 2009 ident: 10.1016/j.yexcr.2022.113442_bib26 article-title: Locked nucleic acid as a novel class of therapeutic agents publication-title: RNA Biol. doi: 10.4161/rna.6.3.8807 – volume: 15 start-page: 338 issue: 3 year: 2018 ident: 10.1016/j.yexcr.2022.113442_bib62 article-title: Anti-miRNA oligonucleotides: a comprehensive guide for design publication-title: RNA Biol. doi: 10.1080/15476286.2018.1445959 – volume: 5 issue: 6 year: 2016 ident: 10.1016/j.yexcr.2022.113442_bib80 article-title: Pharmacokinetics and pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in mice and non-human primates publication-title: Mol. Ther. Nucleic Acids – volume: 2 start-page: 42 issue: 1 year: 1991 ident: 10.1016/j.yexcr.2022.113442_bib114 article-title: Allele-specific polymerase chain reaction publication-title: Methods doi: 10.1016/S1046-2023(05)80124-0 – volume: 118 start-page: 14177 issue: 49 year: 2014 ident: 10.1016/j.yexcr.2022.113442_bib22 article-title: Interplay of LNA and 2'-O-methyl RNA in the structure and thermodynamics of RNA hybrid systems: a molecular dynamics study using the revised AMBER force field and comparison with experimental results publication-title: J. Phys. Chem. B doi: 10.1021/jp506703g – volume: 13 start-page: 909 issue: 4 year: 2018 ident: 10.1016/j.yexcr.2022.113442_bib70 article-title: Targeting of G-quadruplex harboring pre-miRNA 92b by LNA rescues PTEN expression in NSCL cancer cells publication-title: ACS Chem. Biol. doi: 10.1021/acschembio.7b00749 – volume: 18 start-page: 326 issue: 4 year: 2011 ident: 10.1016/j.yexcr.2022.113442_bib90 article-title: Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection publication-title: Gene Ther. doi: 10.1038/gt.2010.133 – volume: 88 start-page: 8902 issue: 17 year: 2016 ident: 10.1016/j.yexcr.2022.113442_bib117 article-title: Probing 3D collective cancer invasion using double-stranded locked nucleic acid biosensors publication-title: Anal. Chem. doi: 10.1021/acs.analchem.6b02608 – volume: 233 start-page: 509 issue: 3 year: 1993 ident: 10.1016/j.yexcr.2022.113442_bib38 article-title: Structure of a DNA:RNA hybrid duplex. Why RNase H does not cleave pure RNA publication-title: J. Mol. Biol. doi: 10.1006/jmbi.1993.1528 – volume: 9 issue: 2 year: 2014 ident: 10.1016/j.yexcr.2022.113442_bib79 article-title: In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells publication-title: PLoS One doi: 10.1371/journal.pone.0089659 – volume: 188 year: 2020 ident: 10.1016/j.yexcr.2022.113442_bib78 article-title: Development and validation of bioanalytical methods for LNA-i-miR-221 quantification in human plasma and urine by LC-MS/MS publication-title: J. Pharmaceut. Biomed. Anal. doi: 10.1016/j.jpba.2020.113451 – start-page: 455 issue: 4 year: 1998 ident: 10.1016/j.yexcr.2022.113442_bib3 article-title: LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition publication-title: Chem. Commun. doi: 10.1039/a708608c – volume: 15 start-page: 4009 issue: 12 year: 2009 ident: 10.1016/j.yexcr.2022.113442_bib74 article-title: Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-08-3257 – volume: 7 year: 2016 ident: 10.1016/j.yexcr.2022.113442_bib34 article-title: Activating frataxin expression by repeat-targeted nucleic acids publication-title: Nat. Commun. – volume: 4 start-page: i issue: 7 year: 2007 ident: 10.1016/j.yexcr.2022.113442_bib124 article-title: MicroRNA profiling of breast cancer tissue using an LNA-based microarray publication-title: Nat. Methods doi: 10.1038/nmeth1067 – volume: 573 year: 2020 ident: 10.1016/j.yexcr.2022.113442_bib68 article-title: Antisense LNA-loaded nanoparticles of star-shaped glucose-core PCL-PEG copolymer for enhanced inhibition of oncomiR-214 and nucleolin-mediated therapy of cisplatin-resistant ovarian cancer cells publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2019.118729 – volume: 117 start-page: 5556 issue: 18 year: 2013 ident: 10.1016/j.yexcr.2022.113442_bib21 article-title: Structures, dynamics, and stabilities of fully modified locked nucleic acid (beta-D-LNA and alpha-L-LNA) duplexes in comparison to pure DNA and RNA duplexes publication-title: J. Phys. Chem. B doi: 10.1021/jp4016068 – volume: 6 start-page: 851 issue: 7 year: 2014 ident: 10.1016/j.yexcr.2022.113442_bib35 article-title: Development of microRNA therapeutics is coming of age publication-title: EMBO Mol. Med. doi: 10.15252/emmm.201100899 – volume: 21 start-page: 74 issue: 2 year: 2003 ident: 10.1016/j.yexcr.2022.113442_bib9 article-title: LNA: a versatile tool for therapeutics and genomics publication-title: Trends Biotechnol. doi: 10.1016/S0167-7799(02)00038-0 – volume: 27 start-page: 1139 issue: 4 year: 2021 ident: 10.1016/j.yexcr.2022.113442_bib71 article-title: Cobomarsen, an oligonucleotide inhibitor of miR-155, slows DLBCL tumor cell growth in vitro and in vivo publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-20-3139 – volume: 25 start-page: 317 issue: 6 year: 2015 ident: 10.1016/j.yexcr.2022.113442_bib105 article-title: Targeting cancer cells using LNA-modified aptamer-siRNA chimeras publication-title: Nucleic Acid Therapeut. doi: 10.1089/nat.2015.0550 – volume: 282 start-page: 23716 issue: 32 year: 2007 ident: 10.1016/j.yexcr.2022.113442_bib128 article-title: miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M701805200 – volume: 32 start-page: e32 issue: 3 year: 2004 ident: 10.1016/j.yexcr.2022.113442_bib17 article-title: Strong positional preference in the interaction of LNA oligonucleotides with DNA polymerase and proofreading exonuclease activities: implications for genotyping assays publication-title: Nucleic Acids Res. doi: 10.1093/nar/gnh036 – volume: 12 issue: 1 year: 2019 ident: 10.1016/j.yexcr.2022.113442_bib81 article-title: Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 publication-title: Cancers doi: 10.3390/cancers12010027 – volume: 406 start-page: 2477 issue: 9–10 year: 2014 ident: 10.1016/j.yexcr.2022.113442_bib113 article-title: High-sensitivity PCR method for detecting BRAF V600E mutations in metastatic colorectal cancer using LNA/DNA chimeras to block wild-type alleles publication-title: Anal. Bioanal. Chem. doi: 10.1007/s00216-014-7618-x – volume: 14 start-page: 130 issue: 2 year: 2004 ident: 10.1016/j.yexcr.2022.113442_bib18 article-title: Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology publication-title: Oligonucleotides doi: 10.1089/1545457041526317 – volume: 1 start-page: S212 issue: 5 year: 2003 ident: 10.1016/j.yexcr.2022.113442_bib56 article-title: 706 in vitro and in vivo efficacy of a HIF-1alpha-antisense oligonucleotide containing locked nucleic acids publication-title: Eur. J. Cancer Suppl. doi: 10.1016/S1359-6349(03)90737-3 – volume: 3 start-page: 9 year: 2011 ident: 10.1016/j.yexcr.2022.113442_bib2 article-title: Epigenetic changes in cancer publication-title: F1000 Biol. Rep. doi: 10.3410/B3-9 – volume: 173 start-page: 405 issue: 173 year: 2006 ident: 10.1016/j.yexcr.2022.113442_bib97 article-title: Locked nucleic acid: high-affinity targeting of complementary RNA for RNomics publication-title: Handb. Exp. Pharmacol. doi: 10.1007/3-540-27262-3_21 – volume: 154 start-page: 520 year: 2016 ident: 10.1016/j.yexcr.2022.113442_bib118 article-title: Direct detection of circulating free DNA extracted from serum samples of breast cancer using locked nucleic acid molecular beacon publication-title: Talanta doi: 10.1016/j.talanta.2016.04.008 – start-page: 1247 issue: 12 year: 1998 ident: 10.1016/j.yexcr.2022.113442_bib13 article-title: Universality of LNA-mediated high-affinity nucleic acid recognition publication-title: Chem. Commun. doi: 10.1039/a801571f – volume: 30 start-page: 2435 issue: 11 year: 2002 ident: 10.1016/j.yexcr.2022.113442_bib45 article-title: Design and characterization of decoy oligonucleotides containing locked nucleic acids publication-title: Nucleic Acids Res. doi: 10.1093/nar/30.11.2435 – volume: 309 start-page: 310 issue: 5732 year: 2005 ident: 10.1016/j.yexcr.2022.113442_bib126 article-title: MicroRNA expression in zebrafish embryonic development publication-title: Science doi: 10.1126/science.1114519 – ident: 10.1016/j.yexcr.2022.113442_bib29 |
| SSID | ssj0008816 |
| Score | 2.5439506 |
| SecondaryResourceType | review_article |
| Snippet | Cancer is responsible for about one in six deaths in the world. Conventional cancer treatments like chemotherapy, radiotherapy, and surgery are associated with... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 113442 |
| SubjectTerms | Cancer Cancer diagnosis Cancer treatment Humans LNA Locked nucleic acid Neoplasms - diagnosis Neoplasms - genetics Neoplasms - therapy Nucleic Acid Conformation Oligonucleotides - chemistry Oligonucleotides - genetics Oligonucleotides - therapeutic use Oligonucleotides, Antisense - chemistry Oligonucleotides, Antisense - genetics Oligonucleotides, Antisense - therapeutic use Quality of Life RNA |
| Title | Locked nucleic acid (LNA): A modern approach to cancer diagnosis and treatment |
| URI | https://dx.doi.org/10.1016/j.yexcr.2022.113442 https://www.ncbi.nlm.nih.gov/pubmed/36521777 https://www.proquest.com/docview/2755575431 |
| Volume | 423 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEB76QPAivq2PsoIHBaPJbp7eSrFULT1Z6G1JZjcQ0bS0KdiLv93dvMBDe_AadslmZjMzy37zfQA3IkaBlolGzEJ1QPF1s3IoLcOnjLkCpcdEjvIdu8OJ_Tp1pg3oV70wGlZZxv4ipufRunzyWFrzcZ4kusdXHQZ86lHtaOYETWhTFrhOC9q9l7fhuA7Ivp8roOrxhp5QkQ_lMK-1_EbNC0qpljexbbopQW0qQPNENNiHvbKCJL1ikQfQkOkh7BSakusjGI9UhJOCpJqoOEESYiLI7Wjcu3siPfKVS5-RikmcZDOC2u8LIgrMXbIkYSpIjT8_hsng-b0_NErRBAOVDTKDBdIXNo1tJ1BnHzOOLDegptTMbMyMYysyhUdV3kcrpoEtRRQxK1RJWmIUy0ggO4FWOkvlGRAnROk6FKmvqhR0aeTKQOp7PgxUijOxA7SyFMeSUVwLW3zyCjr2wXPzcm1eXpi3A_f1pHlBqLF9uFu5gP_ZF1yF_O0TryuHcfXH6GuQMJWz1ZJTz3FUkaoqpw6cFp6sV8LU91qe553_97UXsKsF6Qtc9yW0ssVKXqmyJYu60Hz4sbrl5vwF1i_pXw |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEB5WRfQivl2fETwoWLdN-vS2iLLquicX9hbaSQoV7co-QC_-djN9rHhwD15LQtOZdGZCvvk-gDOVokLHRisVsTmghNSsHGvHCrkQvkIdCFWgfHt-p-8-DLxBA27qXhiCVVaxv4zpRbSunrQqa7bes4x6fM1hIOQBJ0cLL1qAJdcTAeH6rr5-cB5hWOif0miLhtfUQwXI61N_ILGCck7iJq7L_0pPf5WfRRq6W4e1qn5k7XKJG9DQ-SYsl4qSn1vQ65r4phXLiaY4QxZjpth5t9e-uGZt9lYIn7GaR5xNhgzJ6yOmSsRdNmZxrtgMfb4N_bvb55uOVUkmWGgsMLFEpEPl8tT1InPysdPE8SNua-JlE3aaOomtAm6yPjopj1ytkkQ4sUnRGpNUJwrFDizmw1zvAfNi1L7HkYemRkGfJ76ONN3yYWQSnI1N4LWlJFZ84iRr8Spr4NiLLMwrybyyNG8TLmeT3ks6jfnD_doF8teukCbgz594WjtMmv-FLkHiXA-nY8kDzzMlqqmbmrBbenK2EmG-1wmCYP-_rz2Blc7zU1d273uPB7BK0vQlwvsQFiejqT4yBcwkOS426DfIl-oq |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Locked+nucleic+acid+%28LNA%29%3A+A+modern+approach+to+cancer+diagnosis+and+treatment&rft.jtitle=Experimental+cell+research&rft.au=Kamali%2C+Mohammad+Javad&rft.au=Salehi%2C+Mohammad&rft.au=Fatemi%2C+Somayeh&rft.au=Moradi%2C+Fereshteh&rft.date=2023-02-01&rft.issn=0014-4827&rft.volume=423&rft.issue=1&rft.spage=113442&rft_id=info:doi/10.1016%2Fj.yexcr.2022.113442&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_yexcr_2022_113442 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-4827&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-4827&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-4827&client=summon |